Deerfield Management Company, L.P. (Series C) Savara Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Savara Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 7,964,000 shares of SVRA stock, worth $32.5 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
7,964,000
Previous 7,964,000
-0.0%
Holding current value
$32.5 Million
Previous $22.1 Million
17.69%
% of portfolio
0.42%
Previous 0.56%
Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
127Shares Held
167MCall Options Held
38.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD24.5MShares$99.8 Million4.63% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$71.8 Million12.04% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$50.4 Million5.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$46.8 Million1.38% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$44.9 Million1.32% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $465M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.